# Direava

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/direava

- Industry: Medical Devices & Equipment
- Headquarters: Tokyo, Japan
- Website: www.direava.com
- Latest round: Series A (May 21, 2025)
- Investors on record: 2

## About

Founded in 2023 and based in Tokyo, Japan, Direava Co., Ltd., d.b.a Direava, develops AI-powered systems and medical devices for surgical automation and provides related services such as development, sales, and consulting. In June 2026, Direava raised an undisclosed amount ?in venture funding from SPARX Group, SBI Investment and Nissay Capital.

Direava???? focuses on revolutionizing surgical procedures through the integration of artificial intelligence. The company’s core offerings include advanced medical devices that automate surgical processes aimed at reducing complications in surgeries. These products utilize AI algorithms to learn from the skilled techniques of experienced surgeons, effectively creating a navigation system that assists surgeons during operations. By enhancing precision and decision-making, Direava targets various end users, including hospitals, surgical clinics, and medical practitioners who seek innovative solutions to improve patient outcomes. The company has strategically positioned itself in markets across Japan and is expanding internationally, catering to healthcare facilities looking to integrate cutting-edge technology into their surgical practices. Direava???? generates revenue primarily through the sale and leasing of its medical devices and surgical automation systems. The transaction structure typically involves B2B partnerships with healthcare providers and institutions, where clients purchase or lease equipment along with consulting services for implementation and training. The company engages in direct sales to hospitals and clinics, ensuring that their products meet specific operational needs. Additionally, ongoing maintenance and support services are integral to the revenue model, ensuring sustained engagement with clients beyond initial sales. These structured transactions contribute to a comprehensive revenue stream that supports the development and enhancement of their technology offerings.

The company plans to use the June 2026 funding to advance Physical AI for automated surgery, expand globally, strengthen compliance, and hire skilled talent.

## Funding rounds

- Series A, May 21, 2025 — SBI Investment, Nissay Capital

## Investors

- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Series A
- Nissay Capital (https://capitalatlas.ai/funds/nissay-capital) — Series A